Next 10 |
2024-04-05 06:53:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cyclerion Therapeutics (NASDAQ: CYCN ) just reported results for the fourth quarter of 2023. Cyclerion Therapeutics reported earnings per share of -$1.60. The company ...
2023-12-04 09:36:22 ET More on Cyclerion Therapeutics Financial information for Cyclerion Therapeutics For further details see: Cyclerion Therapeutics appoints Graul as President
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a stra...
- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins: Seasoned biopharma executive posses...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Cyclerion Therapeutics Inc. (CYCN) is expected to report for Q1 2024
2023-10-27 16:13:47 ET Summary Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved for multiple GI indications. Ironwood recently a...
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with No Approved Therapies, Leveraging Extensive Preclinical and Clinical Data ...
2023-06-01 16:40:27 ET Cyclerion Therapeutics ( NASDAQ: CYCN ) has received a formal notice from The Nasdaq stating that it has regained compliance with the $1/share minimum bid price requirement pursuant to Nasdaq Listing Rule. In order to regain compliance, the Co. was r...
News, Short Squeeze, Breakout and More Instantly...
Cyclerion Therapeutics Inc. Company Name:
CYCN Stock Symbol:
NYSE Market:
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a de...
– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a stra...